Autoantibody spark response predicts treatment outcome in patients receiving chemoradiation followed by durvalumab therapy

RECOMMENDED

Lung Cancer

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis

★ 1 Recommended by Dr Martin Frey, Faculty Member

Front Oncol

Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M

doi: 10.3389/fonc.2025.1526931

COMMENTED

Asthma

Secondary Non-Response to Biologic Treatment in Patients with Severe Asthma

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

J Asthma Allergy

Mobayed H, Al-Nesf M, Ibrahim T, Aqel S, Al-Ahmad M, Bousquet J

doi: 10.2147/JAA.S517784

COMMENTED

Asthma

The role of bronchial biopsy in the prediction of response to biological therapy in severe uncontrolled asthma: a prospective study

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Chest

Cosío BG, Iglesias A, Shafiek H, Mosteiro M, Escribano I, Toledo-Pons N, Valera JL, Bellvert CG, Pérez de Llano L

doi: 10.1016/j.chest.2024.11.045

RECOMMENDED

Lung Cancer

The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan

★ 1 Recommended by Dr Martin Frey, Faculty Member

Clin Lung Cancer

Roisman LC, Mann S, Basel A, Marei R, Krayim B, Kornev G, Asna N, Peled N

doi: 10.1016/j.cllc.2025.02.002

RECOMMENDED

Asthma

Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Eur Respir J

Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos JP, Roseti SL, Ambrose CS, Hunter G, Jackson DJ, Castro M, Lugogo N, Pavord ID, Martin N, Brightling CE

doi: 10.1183/13993003.00316-2024

RECOMMENDED

Pulmonary Fibrosis

Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: a retrospective registry-based study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Respir Med

Koziar Vašáková M, Gregor J, Mogulkoc N, Kramer MR, Lewandowska K, Šterclová M, Müller V, Slivka R, Studnicka M, Plačková M, Žurková M, Tekavec-Trkanjec J, Doubková M, Ovesná P, EMPIRE investigators

doi: 10.1016/j.rmed.2024.107791

Tuberculosis

Effects of conditional cash transfers and pre-test and post-test tuberculosis counselling on patient outcomes and loss to follow-up across the continuum of care in South Africa: a randomised controlled trial

Lancet Infect Dis

Ismail N, Moultrie H, Mwansa-Kambafwile J, Copas A, Izu A, Moyo S, Skinner D, Ismail F, Gosce L, Omar SV, Abubakar I, Madhi SA

doi: 10.1016/S1473-3099(24)00816-8

RECOMMENDED

Emphysema

Outcome and safety 90 days after combined airway valve treatment of the right upper and middle lobes in patients with severe pulmonary emphysema

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Respir Res

Dittrich AS, De Pace CC, Brock JM, Trudzinski F, Heussel CP, Eberhardt R, Herth FJF, Kontogianni K

doi: 10.1186/s12931-024-03069-6

Lung Cancer

Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC

Clin Lung Cancer

Cantor DJ, Nimeiri H, Horn L, West M, Ben-Shachar R, Huerga I, Patel JD, Aggarwal C

doi: 10.1016/j.cllc.2025.05.007

Related content

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis

Secondary Non-Response to Biologic Treatment in Patients with Severe Asthma

The role of bronchial biopsy in the prediction of response to biological therapy in severe uncontrolled asthma: a prospective study

The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan

Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies

Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: a retrospective registry-based study

Effects of conditional cash transfers and pre-test and post-test tuberculosis counselling on patient outcomes and loss to follow-up across the continuum of care in South Africa: a randomised controlled trial

Outcome and safety 90 days after combined airway valve treatment of the right upper and middle lobes in patients with severe pulmonary emphysema

Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC